Q2 INTERIM REPORT APRIL - JUNE 2022
READ MORE
Mentice acquires Ankyras solutions from Galgo Medical SL
READ MORE

Mentice publishes the company’s interim report for the period January–September 2019

Monday, November 25, 2019

Continued expansion, but the medical device industry is lagging

Third quarter 2019

  • Net sales amounted to 29.3 (35.6) MSEK.
  • Operating result for the period before depreciations (EBITDA) totaled -6.7 (1.3) MSEK.
  • Net result for the period amounted to -9.0 (-0.3) MSEK.
  • Earnings per share (EPS) was -0.37 (-0.03) SEK.
  • Order intake amounted to 24.4 (49.2) MSEK.
  • The order book was 47.0 (55.0) MSEK.
  • Cash flow from operating activities totaled -16.2 (2.9) MSEK.

January-September 2019

  • Net sales amounted to 89.1 (91.9) MSEK.
  • Operating result for the period before depreciations (EBITDA) totaled -24.7 (-3.5) MSEK.
  • Net result for the period amounted to -28.4 (-7.6) MSEK.
  • Earnings per share (EPS) was -1.56 (-0.68) SEK.
  • Order intake amounted to 84.4 (112.4) MSEK.
  • The order book was 47.0 (55.0) MSEK.
  • Cash flow from operating activities totaled -20.6 (3.6) MSEK.

“After the third quarter of the year we are 3.0% below in net sales compared to the same period in 2018, and 24.9% below on orders received. This is still mainly related to a lag in orders in the medical device industry segment. In part we see this as the industry being more cautious when it comes

to spending, but the decision time for these large corporation is also usually long, and we cannot control the timeframe for the final decisions. In view of this, the company deviates from the previous guidance on net sales growth in the lower part of the interval 30-40% for the current financial year” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for January–September 2019 will be presented by CEO Göran Malmberg with the possibility to ask questions on November 25, 2019 at 15:00 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit www.mentice.com/financial-reports-presentations Please make sure to register at least a few minutes in advance.


For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on November 25, 2019 08:30 CET.  

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.

DELÅRSRAPPORT Q2 APRIL - JUNI 2022
LÄS MER
Mentice förvärvar Ankyras från det spanska företaget Galgo Medical S.L.
LÄS MER

Mentice publishes the company’s interim report for the period January–September 2019

Monday, November 25, 2019

Continued expansion, but the medical device industry is lagging

Third quarter 2019

  • Net sales amounted to 29.3 (35.6) MSEK.
  • Operating result for the period before depreciations (EBITDA) totaled -6.7 (1.3) MSEK.
  • Net result for the period amounted to -9.0 (-0.3) MSEK.
  • Earnings per share (EPS) was -0.37 (-0.03) SEK.
  • Order intake amounted to 24.4 (49.2) MSEK.
  • The order book was 47.0 (55.0) MSEK.
  • Cash flow from operating activities totaled -16.2 (2.9) MSEK.

January-September 2019

  • Net sales amounted to 89.1 (91.9) MSEK.
  • Operating result for the period before depreciations (EBITDA) totaled -24.7 (-3.5) MSEK.
  • Net result for the period amounted to -28.4 (-7.6) MSEK.
  • Earnings per share (EPS) was -1.56 (-0.68) SEK.
  • Order intake amounted to 84.4 (112.4) MSEK.
  • The order book was 47.0 (55.0) MSEK.
  • Cash flow from operating activities totaled -20.6 (3.6) MSEK.

“After the third quarter of the year we are 3.0% below in net sales compared to the same period in 2018, and 24.9% below on orders received. This is still mainly related to a lag in orders in the medical device industry segment. In part we see this as the industry being more cautious when it comes

to spending, but the decision time for these large corporation is also usually long, and we cannot control the timeframe for the final decisions. In view of this, the company deviates from the previous guidance on net sales growth in the lower part of the interval 30-40% for the current financial year” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the interim report

Mentice's interim report for January–September 2019 will be presented by CEO Göran Malmberg with the possibility to ask questions on November 25, 2019 at 15:00 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit www.mentice.com/financial-reports-presentations Please make sure to register at least a few minutes in advance.


For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on November 25, 2019 08:30 CET.  

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.